WebTherapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular: HCPCS codes covered if selection criteria are met: J0490: Injection, … WebJun 9, 2024 · Benlysta should be administered by healthcare providers prepared to manage anaphylaxis. SUBQ (adults aged 18 years or older): 200 mg once weekly given as a subcutaneous injection in the abdomen or thingh. If transitioning from IV to subcutaneous, administer the first subcutaneous dose 1 to 4 weeks after the last IV dose.
Benlysta® (belimumab) (Subcutaneous) - Magellan Provider
WebFeb 15, 2024 · Subcutaneous dosing of BENLYSTA has not been evaluated and is not approved for patients younger than 18 years of age. Adult Patients with SLE The … WebBelimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.. The most common side effects include bacterial … michael dewberry md
Benlysta Dosage Guide - Drugs.com
WebAug 17, 2024 · SUBCUTANEOUS: 400 mg (two 200-mg injections) once a week for 4 doses, then 200 mg once a week thereafter in the abdomen or thigh (preferably on the same day … WebJul 21, 2024 · GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody‑positive SLE who are receiving standard therapy. WebFeb 15, 2024 · A patient with lupus nephritis may transition from intravenous therapy with BENLYSTA to subcutaneous therapy any time after the patient completes the first 2 intravenous doses. If transitioning, administer the first subcutaneous dose of 200 mg 1 to 2 weeks after the last intravenous dose. ... Item Code Package Description Marketing Start … michael d gilbride search